Copyright Reports & Markets. All rights reserved.

Global Recombinant Vector Vaccines Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024

Request for Sample of this report
Buy now

Table of Contents

    1 Market Overview

    • 1.1 Recombinant Vector Vaccines Introduction
    • 1.2 Market Analysis by Type
      • 1.2.1 Varicella
      • 1.2.2 Influenza
      • 1.2.3 Polio
      • 1.2.4 Hepatitis A
      • 1.2.5 Rabies
      • 1.2.6 BCG
      • 1.2.7 Hepatitis B
      • 1.2.8 Pertussis, Diphtheria, tetanus
      • 1.2.9 Pneumococcal
      • 1.2.10 Others
    • 1.3 Market Analysis by Applications
      • 1.3.1 For Adult
      • 1.3.2 For Child
    • 1.4 Market Analysis by Regions
      • 1.4.1 North America (United States, Canada and Mexico)
        • 1.4.1.1 United States Market States and Outlook (2014-2024)
        • 1.4.1.2 Canada Market States and Outlook (2014-2024)
        • 1.4.1.3 Mexico Market States and Outlook (2014-2024)
      • 1.4.2 Europe (Germany, France, UK, Russia and Italy)
        • 1.4.2.1 Germany Market States and Outlook (2014-2024)
        • 1.4.2.2 France Market States and Outlook (2014-2024)
        • 1.4.2.3 UK Market States and Outlook (2014-2024)
        • 1.4.2.4 Russia Market States and Outlook (2014-2024)
        • 1.4.2.5 Italy Market States and Outlook (2014-2024)
      • 1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
        • 1.4.3.1 China Market States and Outlook (2014-2024)
        • 1.4.3.2 Japan Market States and Outlook (2014-2024)
        • 1.4.3.3 Korea Market States and Outlook (2014-2024)
        • 1.4.3.4 India Market States and Outlook (2014-2024)
        • 1.4.3.5 Southeast Asia Market States and Outlook (2014-2024)
      • 1.4.4 South America, Middle East and Africa
        • 1.4.4.1 Brazil Market States and Outlook (2014-2024)
        • 1.4.4.2 Egypt Market States and Outlook (2014-2024)
        • 1.4.4.3 Saudi Arabia Market States and Outlook (2014-2024)
        • 1.4.4.4 South Africa Market States and Outlook (2014-2024)
        • 1.4.4.5 Turkey Market States and Outlook (2014-2024)
    • 1.5 Market Dynamics
      • 1.5.1 Market Opportunities
      • 1.5.2 Market Risk
      • 1.5.3 Market Driving Force

    2 Manufacturers Profiles

    • 2.1 SANOFI PASTEUR S.A.
      • 2.1.1 Business Overview
      • 2.1.2 Recombinant Vector Vaccines Type and Applications
        • 2.1.2.1 Product A
        • 2.1.2.2 Product B
      • 2.1.3 SANOFI PASTEUR S.A. Recombinant Vector Vaccines Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
    • 2.2 Novartis
      • 2.2.1 Business Overview
      • 2.2.2 Recombinant Vector Vaccines Type and Applications
        • 2.2.2.1 Product A
        • 2.2.2.2 Product B
      • 2.2.3 Novartis Recombinant Vector Vaccines Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
    • 2.3 GSK
      • 2.3.1 Business Overview
      • 2.3.2 Recombinant Vector Vaccines Type and Applications
        • 2.3.2.1 Product A
        • 2.3.2.2 Product B
      • 2.3.3 GSK Recombinant Vector Vaccines Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
    • 2.4 CNBG
      • 2.4.1 Business Overview
      • 2.4.2 Recombinant Vector Vaccines Type and Applications
        • 2.4.2.1 Product A
        • 2.4.2.2 Product B
      • 2.4.3 CNBG Recombinant Vector Vaccines Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
    • 2.5 ChengDa Bio
      • 2.5.1 Business Overview
      • 2.5.2 Recombinant Vector Vaccines Type and Applications
        • 2.5.2.1 Product A
        • 2.5.2.2 Product B
      • 2.5.3 ChengDa Bio Recombinant Vector Vaccines Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
    • 2.6 Changsheng Life
      • 2.6.1 Business Overview
      • 2.6.2 Recombinant Vector Vaccines Type and Applications
        • 2.6.2.1 Product A
        • 2.6.2.2 Product B
      • 2.6.3 Changsheng Life Recombinant Vector Vaccines Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
    • 2.7 Zhifei
      • 2.7.1 Business Overview
      • 2.7.2 Recombinant Vector Vaccines Type and Applications
        • 2.7.2.1 Product A
        • 2.7.2.2 Product B
      • 2.7.3 Zhifei Recombinant Vector Vaccines Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
    • 2.8 SINOVAC BIOTECH
      • 2.8.1 Business Overview
      • 2.8.2 Recombinant Vector Vaccines Type and Applications
        • 2.8.2.1 Product A
        • 2.8.2.2 Product B
      • 2.8.3 SINOVAC BIOTECH Recombinant Vector Vaccines Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
    • 2.9 NuoCheng Bio
      • 2.9.1 Business Overview
      • 2.9.2 Recombinant Vector Vaccines Type and Applications
        • 2.9.2.1 Product A
        • 2.9.2.2 Product B
      • 2.9.3 NuoCheng Bio Recombinant Vector Vaccines Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
    • 2.10 Hualan Bio
      • 2.10.1 Business Overview
      • 2.10.2 Recombinant Vector Vaccines Type and Applications
        • 2.10.2.1 Product A
        • 2.10.2.2 Product B
      • 2.10.3 Hualan Bio Recombinant Vector Vaccines Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
    • 2.11 Kangtai
      • 2.11.1 Business Overview
      • 2.11.2 Recombinant Vector Vaccines Type and Applications
        • 2.11.2.1 Product A
        • 2.11.2.2 Product B
      • 2.11.3 Kangtai Recombinant Vector Vaccines Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)

    3 Global Recombinant Vector Vaccines Sales, Revenue, Market Share and Competition by Manufacturer (2017-2018)

    • 3.1 Global Recombinant Vector Vaccines Sales and Market Share by Manufacturer (2017-2018)
    • 3.2 Global Recombinant Vector Vaccines Revenue and Market Share by Manufacturer (2017-2018)
    • 3.3 Market Concentration Rate
      • 3.3.1 Top 3 Recombinant Vector Vaccines Manufacturer Market Share in 2018
      • 3.3.2 Top 6 Recombinant Vector Vaccines Manufacturer Market Share in 2018
    • 3.4 Market Competition Trend

    4 Global Recombinant Vector Vaccines Market Analysis by Regions

    • 4.1 Global Recombinant Vector Vaccines Sales, Revenue and Market Share by Regions
      • 4.1.1 Global Recombinant Vector Vaccines Sales and Market Share by Regions (2014-2019)
      • 4.1.2 Global Recombinant Vector Vaccines Revenue and Market Share by Regions (2014-2019)
    • 4.2 North America Recombinant Vector Vaccines Sales and Growth Rate (2014-2019)
    • 4.3 Europe Recombinant Vector Vaccines Sales and Growth Rate (2014-2019)
    • 4.4 Asia-Pacific Recombinant Vector Vaccines Sales and Growth Rate (2014-2019)
    • 4.5 South America Recombinant Vector Vaccines Sales and Growth Rate (2014-2019)
    • 4.6 Middle East and Africa Recombinant Vector Vaccines Sales and Growth Rate (2014-2019)

    5 North America Recombinant Vector Vaccines by Country

    • 5.1 North America Recombinant Vector Vaccines Sales, Revenue and Market Share by Country
      • 5.1.1 North America Recombinant Vector Vaccines Sales and Market Share by Country (2014-2019)
      • 5.1.2 North America Recombinant Vector Vaccines Revenue and Market Share by Country (2014-2019)
    • 5.2 United States Recombinant Vector Vaccines Sales and Growth Rate (2014-2019)
    • 5.3 Canada Recombinant Vector Vaccines Sales and Growth Rate (2014-2019)
    • 5.4 Mexico Recombinant Vector Vaccines Sales and Growth Rate (2014-2019)

    6 Europe Recombinant Vector Vaccines by Country

    • 6.1 Europe Recombinant Vector Vaccines Sales, Revenue and Market Share by Country
      • 6.1.1 Europe Recombinant Vector Vaccines Sales and Market Share by Country (2014-2019)
      • 6.1.2 Europe Recombinant Vector Vaccines Revenue and Market Share by Country (2014-2019)
    • 6.2 Germany Recombinant Vector Vaccines Sales and Growth Rate (2014-2019)
    • 6.3 UK Recombinant Vector Vaccines Sales and Growth Rate (2014-2019)
    • 6.4 France Recombinant Vector Vaccines Sales and Growth Rate (2014-2019)
    • 6.5 Russia Recombinant Vector Vaccines Sales and Growth Rate (2014-2019)
    • 6.6 Italy Recombinant Vector Vaccines Sales and Growth Rate (2014-2019)

    7 Asia-Pacific Recombinant Vector Vaccines by Country

    • 7.1 Asia-Pacific Recombinant Vector Vaccines Sales, Revenue and Market Share by Country
      • 7.1.1 Asia-Pacific Recombinant Vector Vaccines Sales and Market Share by Country (2014-2019)
      • 7.1.2 Asia-Pacific Recombinant Vector Vaccines Revenue and Market Share by Country (2014-2019)
    • 7.2 China Recombinant Vector Vaccines Sales and Growth Rate (2014-2019)
    • 7.3 Japan Recombinant Vector Vaccines Sales and Growth Rate (2014-2019)
    • 7.4 Korea Recombinant Vector Vaccines Sales and Growth Rate (2014-2019)
    • 7.5 India Recombinant Vector Vaccines Sales and Growth Rate (2014-2019)
    • 7.6 Southeast Asia Recombinant Vector Vaccines Sales and Growth Rate (2014-2019)

    8 South America Recombinant Vector Vaccines by Country

    • 8.1 South America Recombinant Vector Vaccines Sales, Revenue and Market Share by Country
      • 8.1.1 South America Recombinant Vector Vaccines Sales and Market Share by Country (2014-2019)
      • 8.1.2 South America Recombinant Vector Vaccines Revenue and Market Share by Country (2014-2019)
    • 8.2 Brazil Recombinant Vector Vaccines Sales and Growth Rate (2014-2019)
    • 8.3 Argentina Recombinant Vector Vaccines Sales and Growth Rate (2014-2019)
    • 8.4 Colombia Recombinant Vector Vaccines Sales and Growth Rate (2014-2019)

    9 Middle East and Africa Recombinant Vector Vaccines by Countries

    • 9.1 Middle East and Africa Recombinant Vector Vaccines Sales, Revenue and Market Share by Country
      • 9.1.1 Middle East and Africa Recombinant Vector Vaccines Sales and Market Share by Country (2014-2019)
      • 9.1.2 Middle East and Africa Recombinant Vector Vaccines Revenue and Market Share by Country (2014-2019)
    • 9.2 Saudi Arabia Recombinant Vector Vaccines Sales and Growth Rate (2014-2019)
    • 9.3 Turkey Recombinant Vector Vaccines Sales and Growth Rate (2014-2019)
    • 9.4 Egypt Recombinant Vector Vaccines Sales and Growth Rate (2014-2019)
    • 9.5 Nigeria Recombinant Vector Vaccines Sales and Growth Rate (2014-2019)
    • 9.6 South Africa Recombinant Vector Vaccines Sales and Growth Rate (2014-2019)

    10 Global Recombinant Vector Vaccines Market Segment by Type

    • 10.1 Global Recombinant Vector Vaccines Sales, Revenue and Market Share by Type (2014-2019)
      • 10.1.1 Global Recombinant Vector Vaccines Sales and Market Share by Type (2014-2019)
      • 10.1.2 Global Recombinant Vector Vaccines Revenue and Market Share by Type (2014-2019)
    • 10.2 Varicella Sales Growth and Price
      • 10.2.1 Global Varicella Sales Growth (2014-2019)
      • 10.2.2 Global Varicella Price (2014-2019)
    • 10.3 Influenza Sales Growth and Price
      • 10.3.1 Global Influenza Sales Growth (2014-2019)
      • 10.3.2 Global Influenza Price (2014-2019)
    • 10.4 Polio Sales Growth and Price
      • 10.4.1 Global Polio Sales Growth (2014-2019)
      • 10.4.2 Global Polio Price (2014-2019)
    • 10.5 Hepatitis A Sales Growth and Price
      • 10.5.1 Global Hepatitis A Sales Growth (2014-2019)
      • 10.5.2 Global Hepatitis A Price (2014-2019)
    • 10.6 Rabies Sales Growth and Price
      • 10.6.1 Global Rabies Sales Growth (2014-2019)
      • 10.6.2 Global Rabies Price (2014-2019)
    • 10.7 BCG Sales Growth and Price
      • 10.7.1 Global BCG Sales Growth (2014-2019)
      • 10.7.2 Global BCG Price (2014-2019)
    • 10.8 Hepatitis B Sales Growth and Price
      • 10.8.1 Global Hepatitis B Sales Growth (2014-2019)
      • 10.8.2 Global Hepatitis B Price (2014-2019)
    • 10.9 Pertussis, Diphtheria, tetanus Sales Growth and Price
      • 10.9.1 Global Pertussis, Diphtheria, tetanus Sales Growth (2014-2019)
      • 10.9.2 Global Pertussis, Diphtheria, tetanus Price (2014-2019)
    • 10.10 Pneumococcal Sales Growth and Price
      • 10.10.1 Global Pneumococcal Sales Growth (2014-2019)
      • 10.10.2 Global Pneumococcal Price (2014-2019)
    • 10.11 Others Sales Growth and Price
      • 10.11.1 Global Others Sales Growth (2014-2019)
      • 10.11.2 Global Others Price (2014-2019)

    11 Global Recombinant Vector Vaccines Market Segment by Application

    • 11.1 Global Recombinant Vector Vaccines Sales Market Share by Application (2014-2019)
    • 11.2 For Adult Sales Growth (2014-2019)
    • 11.3 For Child Sales Growth (2014-2019)

    12 Recombinant Vector Vaccines Market Forecast (2019-2024)

    • 12.1 Global Recombinant Vector Vaccines Sales, Revenue and Growth Rate (2019-2024)
    • 12.2 Recombinant Vector Vaccines Market Forecast by Regions (2019-2024)
      • 12.2.1 North America Recombinant Vector Vaccines Market Forecast (2019-2024)
      • 12.2.2 Europe Recombinant Vector Vaccines Market Forecast (2019-2024)
      • 12.2.3 Asia-Pacific Recombinant Vector Vaccines Market Forecast (2019-2024)
      • 12.2.4 South America Recombinant Vector Vaccines Market Forecast (2019-2024)
      • 12.2.5 Middle East and Africa Recombinant Vector Vaccines Market Forecast (2019-2024)
    • 12.3 Recombinant Vector Vaccines Market Forecast by Type (2019-2024)
      • 12.3.1 Global Recombinant Vector Vaccines Sales Forecast by Type (2019-2024)
      • 12.3.2 Global Recombinant Vector Vaccines Market Share Forecast by Type (2019-2024)
    • 12.4 Recombinant Vector Vaccines Market Forecast by Application (2019-2024)
      • 12.4.1 Global Recombinant Vector Vaccines Sales Forecast by Application (2019-2024)
      • 12.4.2 Global Recombinant Vector Vaccines Market Share Forecast by Application (2019-2024)

    13 Sales Channel, Distributors, Traders and Dealers

    • 13.1 Sales Channel
      • 13.1.1 Direct Marketing
      • 13.1.2 Indirect Marketing
      • 13.1.3 Marketing Channel Future Trend
    • 13.2 Distributors, Traders and Dealers

    14 Research Findings and Conclusion

      15 Appendix

      • 15.1 Methodology

      Recombinant vector vaccines are experimental vaccines similar to DNA vaccines, but they use an attenuated virus or bacterium to introduce microbial DNA to cells of the body. “Vector” refers to the virus or bacterium used as the carrier.
      In nature, viruses latch on to cells and inject their genetic material into them. In the lab, scientists have taken advantage of this process. They have figured out how to take the roomy genomes of certain harmless or attenuated viruses and insert portions of the genetic material from other microbes into them. The carrier viruses then ferry that microbial DNA to cells. Recombinant vector vaccines closely mimic a natural infection and therefore do a good job of stimulating the immune system.
      Attenuated bacteria also can be used as vectors. In this case, the inserted genetic material causes the bacteria to display the antigens of other microbes on its surface. In effect, the harmless bacterium mimics a harmful microbe, provoking an immune response.
      Researchers are working on both bacteria-l and viral-based recombinant vector vaccines for HIV, rabies, and measles.

      Scope of the Report:
      The worldwide market for Recombinant Vector Vaccines is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2024, from xx million US$ in 2019, according to a new GIR (Global Info Research) study.
      This report focuses on the Recombinant Vector Vaccines in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

      Market Segment by Manufacturers, this report covers
      SANOFI PASTEUR S.A.
      Novartis
      GSK
      CNBG
      ChengDa Bio
      Changsheng Life
      Zhifei
      SINOVAC BIOTECH
      NuoCheng Bio
      Hualan Bio
      Kangtai

      Market Segment by Regions, regional analysis covers
      North America (United States, Canada and Mexico)
      Europe (Germany, France, UK, Russia and Italy)
      Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
      South America (Brazil, Argentina, Colombia etc.)
      Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

      Market Segment by Type, covers
      Varicella
      Influenza
      Polio
      Hepatitis A
      Rabies
      BCG
      Hepatitis B
      Pertussis, Diphtheria, tetanus
      Pneumococcal
      Others

      Market Segment by Applications, can be divided into
      For Adult
      For Child

      The content of the study subjects, includes a total of 15 chapters:
      Chapter 1, to describe Recombinant Vector Vaccines product scope, market overview, market opportunities, market driving force and market risks.
      Chapter 2, to profile the top manufacturers of Recombinant Vector Vaccines, with price, sales, revenue and global market share of Recombinant Vector Vaccines in 2017 and 2018.
      Chapter 3, the Recombinant Vector Vaccines competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
      Chapter 4, the Recombinant Vector Vaccines breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
      Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
      Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
      Chapter 12, Recombinant Vector Vaccines market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
      Chapter 13, 14 and 15, to describe Recombinant Vector Vaccines sales channel, distributors, customers, research findings and conclusion, appendix and data source.

      Buy now